히스톤 탈아세틸화효소(HDAC) 억제제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 7.5%의 CAGR로 17억 7,000만 달러 규모에 이를 것으로 예상됩니다. 예측 기간 동안 성장의 배경에는 신경 퇴행성 질환의 발병률 증가, 암에 대한 인식 증가, 의약품 개발에 대한 투자 증가, 임상시험 수 증가, 맞춤형 의료의 채택 증가 등이 있습니다. 예측 기간 동안 주요 동향으로는 기술 발전, 맞춤의료, 암 면역치료의 시너지 효과, 디지털 헬스 솔루션의 통합, 바이오인포매틱스 등을 꼽을 수 있습니다.
신경퇴행성 질환의 유병률 증가는 히스톤 탈아세틸화효소(HDAC) 억제제 시장의 성장을 촉진할 것으로 예상됩니다. 신경퇴행성 질환은 뇌와 척수 신경세포의 퇴행과 사멸이 진행되어 인지장애와 운동장애를 유발하는 질환입니다. 여기에는 아밀로이드 플라크와 타우의 엉킴으로 인한 기억 상실과 인지 기능 저하를 특징으로 하는 알츠하이머병과 같은 질환이 포함됩니다. 신경 퇴행성 질환의 증가는 노화, 유전, 장수, 환경적 영향 등의 요인과 관련이 있으며, HDAC 억제제는 유전자 발현을 조절하고 신경 보호 작용을 발휘하기 때문에 이러한 질환의 잠재적 치료제로 연구되고 있습니다. 예를 들어, 2024년 8월 미국 연방정부 기관인 질병통제예방센터(CDC)는 현재 미국에서 약 670만 명의 노인이 알츠하이머병을 앓고 있으며, 2060년까지 그 수가 거의 두 배인 1,400만 명에 달할 것으로 예측했습니다. 이에 따라 신경퇴행성 질환의 발병률 증가가 HDAC 억제제 시장 확대에 박차를 가하고 있습니다.
HDAC 억제제 시장의 주요 기업들은 암 치료용 HDAC 억제제 등 효능을 향상시키고 부작용을 최소화하기 위한 새로운 치료법 개발에 주력하고 있습니다. 작용합니다. 이 저해로 인해 히스톤의 아세틸화가 진행되어 크로마틴 구조가 변화하고 유전자 발현에 영향을 미치게 됩니다. 예를 들어, 2023년 9월 미국의 선구적인 암 치료 전문 기업인 셔틀 파마슈티컬스 홀딩스(Shuttle Pharmaceuticals Holdings)는 미국 특허청으로부터 암 치료를 목표로 하는 HDAC 억제제에 대한 새로운 특허를 취득했습니다. 이 새로운 억제제는 암 진행과 관련된 특정 HDAC 효소를 표적으로 하여 종양 발생 및 전이와 관련된 비정상적인 유전자 발현을 파괴하는 것을 목표로 하고 있습니다. 이 특허 화합물은 효능과 선택성을 개선하고, 표적 외 효과를 줄이며, 환자에 대한 안전성을 높였습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 히스톤 탈아세틸화효소(HDAC) 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 성장률 분석
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 히스톤 탈아세틸화효소(HDAC) 억제제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 클래스 I HDAC
- 클래스 II HDAC
- 클래스 III HDAC
- 클래스 IV HDAC
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 HDAC 억제제
- 비경구 HDAC 억제제
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 종양학
- 신경학
- 기타 용도
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 학술연구기관
- 제약회사
- 기타 최종사용자
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장, 클래스 I HDAC 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- HDAC1
- HDAC2
- HDAC3
- HDAC8
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장, 클래스 II HDAC 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- HDAC4
- HDAC5
- HDAC6
- HDAC7
- HDAC9
- HDAC10
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장, 클래스 III HDAC(시트루인) 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
- SIRT1
- SIRT2
- SIRT3
- SIRT4
- SIRT5
- SIRT6
- SIRT7
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장, 클래스 IV HDAC 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- HDAC11
제7장 지역별·국가별 분석
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 경쟁 구도
- 히스톤 탈아세틸화효소(HDAC) 억제제 시장 : 기업 개요
- Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- Abcam plc Overview, Products and Services, Strategy and Financial Analysis
- Pharmacyclics LLC Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- R&D Systems Inc.
- Tenaya Therapeutics Inc.
- Syndax Pharmaceuticals Inc.
- Italfarmaco SpA
- InvivoGen Corporation
- TCI Chemicals(India) Pvt. Ltd.
- 4SC AG
- Medivir AB
- Mirati Therapeutics Inc.
- Spectrum Pharmaceuticals Inc.
- Curis Inc.
- Acetylon Pharmaceuticals Inc.
- Oryzon Genomics SA
- Xynomic Pharmaceuticals Inc.
- Celleron Therapeutics Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 히스톤 탈아세틸화효소(HDAC) 억제제 시장 2029 : 새로운 기회를 제공하는 국가
- 히스톤 탈아세틸화효소(HDAC) 억제제 시장 2029 : 새로운 기회를 제공하는 부문
- 히스톤 탈아세틸화효소(HDAC) 억제제 시장 2029 : 성장 전략
제36장 부록
ksm
Histone deacetylase (HDAC) inhibitors are a category of compounds that inhibit the activity of histone deacetylase enzymes. These enzymes are responsible for the removal of acetyl groups from histone proteins, resulting in a more compact chromatin structure and decreased gene expression. By promoting hyperacetylation of histones, HDAC inhibitors generally lead to a more open chromatin structure, making DNA more accessible to transcription factors.
Histone deacetylase (HDAC) inhibitors are categorized into four main classes class I, class II, class III, and class IV HDACs. Class I HDACs primarily regulate gene expression by altering chromatin structure and are involved in numerous cellular processes. They are extensively researched for their potential use in treating cancer and other diseases. HDAC inhibitors can be administered orally or parenterally and are applied in fields such as oncology and neurology. They are utilized by various end users, including hospitals, academic and research institutes, and pharmaceutical companies.
The histone deacetylase (HDAC) inhibitors market research report is one of a series of new reports from The Business Research Company that provides histone deacetylase (HDAC) inhibitors market statistics, including histone deacetylase (HDAC) inhibitors industry global market size, regional shares, competitors with a histone deacetylase (HDAC) inhibitors market share, detailed histone deacetylase (HDAC) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the histone deacetylase (HDAC) inhibitors industry. This histone deacetylase (HDAC) inhibitors research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The histone deacetylase (HDAC) inhibitors market size has grown strongly in recent years. It will grow from $1.23 billion in 2024 to $1.33 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to a rise in funding for epigenetic research, rising prevalence of drug-resistant cancers, rise in healthcare expenditure, increasing utilization of HDAC inhibitors in veterinary medicine, and increasing investment in bioinformatics.
The histone deacetylase (HDAC) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to the rising incidence of neurodegenerative disorders, growing awareness about cancer, rising investment in drug development, growing number of clinical trials, and increasing adoption of personalized medicine. Major trends in the forecast period include technological advancements, personalized medicine, cancer immunotherapy synergies, integration of digital health solutions, and bioinformatics.
The increasing prevalence of neurodegenerative disorders is expected to drive the growth of the histone deacetylase (HDAC) inhibitors market. Neurodegenerative disorders, which involve the progressive degeneration and death of neurons in the brain and spinal cord, result in cognitive and motor impairments. These include conditions like Alzheimer's disease, characterized by memory loss and cognitive decline due to amyloid plaques and tau tangles. The rise in neurodegenerative disorders is linked to factors such as aging, genetics, longevity, and environmental influences. HDAC inhibitors are being investigated as potential treatments for these disorders because of their ability to regulate gene expression and offer neuroprotective effects. For example, in August 2024, the Centers for Disease Control and Prevention (CDC), a US federal agency, reported that approximately 6.7 million older adults in the United States are currently living with Alzheimer's disease, a number projected to nearly double to 14 million by 2060. As a result, the growing incidence of neurodegenerative diseases is fueling the expansion of the HDAC inhibitors market.
Key players in the HDAC inhibitors market are concentrating on developing novel treatments, such as HDAC inhibitors for cancer therapy, to improve efficacy and minimize side effects. HDAC inhibitors are a class of drugs used in cancer therapy that work by blocking HDAC enzymes, which usually remove acetyl groups from histone proteins. This blockage results in increased acetylation of histones, altering chromatin structure and affecting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based firm specializing in pioneering cancer therapies, received new patents from the U.S. Patent and Trademark Office for HDAC inhibitors targeting cancer treatment. These new inhibitors are designed to target specific HDAC enzymes associated with cancer progression, aiming to disrupt abnormal gene expression linked to tumor development and spread. The patented compounds offer improved potency and selectivity, reducing off-target effects and enhancing safety for patients.
In June 2024, Italfarmaco SpA, a US-based pharmaceutical company, formed a partnership with Iktos SA for an undisclosed amount. This collaboration aims to accelerate drug discovery in non-oncological areas by utilizing AI to design advanced HDAC inhibitors. Iktos SA is a France-based technology company specializing in artificial intelligence solutions for medicinal chemistry and drug discovery.
Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the histone deacetylase (HDAC) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The histone deacetylase (HDAC) inhibitors market consists of sales of valproic acid, hydroxamic acids, cyclic peptides, short-chain fatty acids, and benzamides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Histone Deacetylase (HDAC) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on histone deacetylase (hdac) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for histone deacetylase (hdac) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The histone deacetylase (hdac) inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Class: Class I HDACs; Class II HDACs; Class III HDACs; Class IV HDACs
- 2) By Route Of Administration: Oral HDAC Inhibitors; Parenteral HDAC Inhibitors
- 3) By Application: Oncology; Neurology; Other Applications
- 4) By End User: Hospitals; Academic And Research Institutes; Pharmaceutical Companies; Other End Users
Subsegments
- 1) By Class I HDACs: HDAC1; HDAC2; HDAC3; HDAC8
- 2) By Class II HDACs: HDAC4; HDAC5; HDAC6; HDAC7; HDAC9; HDAC10
- 3) By Class III HDACs (Sirtuins): SIRT1; SIRT2; SIRT3; SIRT4; SIRT5; SIRT6; SIRT7
- 4) By Class IV HDACs: HDAC11
- Companies Mentioned: Bristol-Myers Squibb Company; Novartis AG; Merck KGaA; Abcam plc; Pharmacyclics LLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Histone Deacetylase (HDAC) Inhibitors Market Characteristics
3. Histone Deacetylase (HDAC) Inhibitors Market Trends And Strategies
4. Histone Deacetylase (HDAC) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Histone Deacetylase (HDAC) Inhibitors Growth Analysis And Strategic Analysis Framework
- 5.1. Global Histone Deacetylase (HDAC) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Histone Deacetylase (HDAC) Inhibitors Market Growth Rate Analysis
- 5.4. Global Histone Deacetylase (HDAC) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Histone Deacetylase (HDAC) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Histone Deacetylase (HDAC) Inhibitors Total Addressable Market (TAM)
6. Histone Deacetylase (HDAC) Inhibitors Market Segmentation
- 6.1. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Class I HDACs
- Class II HDACs
- Class III HDACs
- Class IV HDACs
- 6.2. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral HDAC Inhibitors
- Parenteral HDAC Inhibitors
- 6.3. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oncology
- Neurology
- Others Applications
- 6.4. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Academic And Research Institutes
- Pharmaceutical Companies
- Other End Users
- 6.5. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class I HDACs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- HDAC1
- HDAC2
- HDAC3
- HDAC8
- 6.6. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class II HDACs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- HDAC4
- HDAC5
- HDAC6
- HDAC7
- HDAC9
- HDAC10
- 6.7. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class III HDACs (Sirtuins), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- SIRT1
- SIRT2
- SIRT3
- SIRT4
- SIRT5
- SIRT6
- SIRT7
- 6.8. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class IV HDACs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- HDAC11
7. Histone Deacetylase (HDAC) Inhibitors Market Regional And Country Analysis
- 7.1. Global Histone Deacetylase (HDAC) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Histone Deacetylase (HDAC) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market
- 8.1. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Histone Deacetylase (HDAC) Inhibitors Market
- 9.1. China Histone Deacetylase (HDAC) Inhibitors Market Overview
- 9.2. China Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Histone Deacetylase (HDAC) Inhibitors Market
- 10.1. India Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Histone Deacetylase (HDAC) Inhibitors Market
- 11.1. Japan Histone Deacetylase (HDAC) Inhibitors Market Overview
- 11.2. Japan Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Histone Deacetylase (HDAC) Inhibitors Market
- 12.1. Australia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Histone Deacetylase (HDAC) Inhibitors Market
- 13.1. Indonesia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Histone Deacetylase (HDAC) Inhibitors Market
- 14.1. South Korea Histone Deacetylase (HDAC) Inhibitors Market Overview
- 14.2. South Korea Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Histone Deacetylase (HDAC) Inhibitors Market
- 15.1. Western Europe Histone Deacetylase (HDAC) Inhibitors Market Overview
- 15.2. Western Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Histone Deacetylase (HDAC) Inhibitors Market
- 16.1. UK Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Histone Deacetylase (HDAC) Inhibitors Market
- 17.1. Germany Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Histone Deacetylase (HDAC) Inhibitors Market
- 18.1. France Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Histone Deacetylase (HDAC) Inhibitors Market
- 19.1. Italy Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Histone Deacetylase (HDAC) Inhibitors Market
- 20.1. Spain Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market
- 21.1. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market Overview
- 21.2. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Histone Deacetylase (HDAC) Inhibitors Market
- 22.1. Russia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Histone Deacetylase (HDAC) Inhibitors Market
- 23.1. North America Histone Deacetylase (HDAC) Inhibitors Market Overview
- 23.2. North America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Histone Deacetylase (HDAC) Inhibitors Market
- 24.1. USA Histone Deacetylase (HDAC) Inhibitors Market Overview
- 24.2. USA Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Histone Deacetylase (HDAC) Inhibitors Market
- 25.1. Canada Histone Deacetylase (HDAC) Inhibitors Market Overview
- 25.2. Canada Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Histone Deacetylase (HDAC) Inhibitors Market
- 26.1. South America Histone Deacetylase (HDAC) Inhibitors Market Overview
- 26.2. South America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Histone Deacetylase (HDAC) Inhibitors Market
- 27.1. Brazil Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Histone Deacetylase (HDAC) Inhibitors Market
- 28.1. Middle East Histone Deacetylase (HDAC) Inhibitors Market Overview
- 28.2. Middle East Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Histone Deacetylase (HDAC) Inhibitors Market
- 29.1. Africa Histone Deacetylase (HDAC) Inhibitors Market Overview
- 29.2. Africa Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Histone Deacetylase (HDAC) Inhibitors Market Competitive Landscape And Company Profiles
- 30.1. Histone Deacetylase (HDAC) Inhibitors Market Competitive Landscape
- 30.2. Histone Deacetylase (HDAC) Inhibitors Market Company Profiles
- 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abcam plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Pharmacyclics LLC Overview, Products and Services, Strategy and Financial Analysis
31. Histone Deacetylase (HDAC) Inhibitors Market Other Major And Innovative Companies
- 31.1. R&D Systems Inc.
- 31.2. Tenaya Therapeutics Inc.
- 31.3. Syndax Pharmaceuticals Inc.
- 31.4. Italfarmaco SpA
- 31.5. InvivoGen Corporation
- 31.6. TCI Chemicals (India) Pvt. Ltd.
- 31.7. 4SC AG
- 31.8. Medivir AB
- 31.9. Mirati Therapeutics Inc.
- 31.10. Spectrum Pharmaceuticals Inc.
- 31.11. Curis Inc.
- 31.12. Acetylon Pharmaceuticals Inc.
- 31.13. Oryzon Genomics SA
- 31.14. Xynomic Pharmaceuticals Inc.
- 31.15. Celleron Therapeutics Ltd.
32. Global Histone Deacetylase (HDAC) Inhibitors Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Histone Deacetylase (HDAC) Inhibitors Market
34. Recent Developments In The Histone Deacetylase (HDAC) Inhibitors Market
35. Histone Deacetylase (HDAC) Inhibitors Market High Potential Countries, Segments and Strategies
- 35.1 Histone Deacetylase (HDAC) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Histone Deacetylase (HDAC) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Histone Deacetylase (HDAC) Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
